Piramal Enterprises Ltd
Market Cap.: ₹ 30,833.82 Cr.
Current Price: ₹ 1,786.95
Book Value: ₹ 751.05
Stock P/E: 30.98
Dividend Yield: 0.98%
Face Value: ₹ 2.00… 126 more words
After market close on January 19, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) reported that it had achieved FDA approval for its lead drug, plecanatide, in constipation-predominant…
Top drugmakers have joined with governments and nonprofits around the world to launch an alliance that’ll take a proactive approach to potential deadly outbreaks. Dubbed the…
The U.S. Food and Drug Administration has announced last Thursday its approval of Synergy Pharmaceuticals’s oral treatment for chronic idiopathic constipation (CIC). The one-a-day tablet,…
US-based pharma company Panacea Pharmaceuticals has enrolled the first patient on its phase 1 clinical trial investigating its first-in-class vaccine for persistent prostate cancer.
The four-site trial, being carried out in centres in Alabama, California, Nebraska and South Carolina, is investigating Panacea’s PAN-301-1 candidate – a vaccine that stimulates the immune system to destroy prostate cancer cells. 397 more words